Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests

Ovarian Cancer Patients Benefit from Lynparza Maintenance Tablets, Trial Suggests
Ovarian cancer patients who have an inherited BRCA mutation, and who responded to platinum-based chemotherapy, benefit from using Lynparza (olaparib) tablets as a maintenance treatment, a clinical trial suggests. The Phase 3 SOLO-2 trial (NCT01874353) of the AstraZeneca therapy in tablet form met its primary goal of increasing patients’ progression-free survival — the length of

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *